A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms CheckMate 848
- Sponsors Bristol-Myers Squibb
- 25 Jan 2019 Planned number of patients changed from 199 to 800.
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.
- 08 Oct 2018 Planned initiation date changed from 28 Sep 2018 to 23 Oct 2018.